Today: 21 May 2026
BHP share price slides after Jansen potash cost jump and China iron ore discounts
20 January 2026
2 mins read

BHP share price slides after Jansen potash cost jump and China iron ore discounts

Sydney, January 20, 2026, 17:06 AEDT — Market closed

  • BHP shares fell roughly 2% following the miner’s warning of weaker realised iron ore prices and a higher cost projection for its Jansen Stage 1 potash project
  • The company maintained its full-year iron ore forecast but raised its copper outlook
  • Investors are focusing on China’s iron ore contract negotiations and February results for clearer insights into pricing and costs

BHP Group Ltd (ASX: BHP) shares finished Tuesday down 2%, slipping to A$47.78. The miner cited pricing pressure linked to ongoing iron ore contract negotiations in China and announced an increased budget for its Jansen Stage 1 potash project in Canada.

The timing feels off. Iron ore remains the backbone of BHP’s cash flow, even as the company pushes to expand its potash and copper earnings. All this, while trying to keep costs in check.

China finds itself at the heart of both trends. Its crude steel production dropped to 960.81 million metric tons in 2025, hitting the lowest level since 2018. Analysts are forecasting a further dip in 2026, fueling uncertainty around iron ore demand and prices.

BHP confirmed it has agreed to reduced prices on certain iron ore shipments while hashing out 2026 supply deals with China Mineral Resources Group (CMRG), the state-backed purchaser pressing for greater influence over pricing. The “realised price” refers to what the miner effectively pockets after applying discounts and contract specifics, rather than the headline index.

The company posted record iron ore output of 146.6 million metric tons from its Western Australia operations in the first half. It maintained its full-year iron ore guidance at 284 million to 296 million tons and raised its copper production forecast to 1.9 million to 2.0 million tons. RBC Capital Markets analyst Kaan Peker noted that CMRG’s restrictions might “tighten spot market availability,” potentially boosting the benchmark price, but also warned this could mean steeper discounts for BHP. Reuters

BHP raised its total investment forecast for Jansen Stage 1 potash project to $8.4 billion, up from the previous $7.0 billion to $7.4 billion range, due to revised construction hours and material costs. The first production is now slated for mid-2027. According to the company, Stage 1 is roughly 75% complete. Brandon Craig, president of BHP Americas, described Jansen as “a long-life, low-cost, expandable asset” key to BHP’s growth strategy. BHP

Chief executive Mike Henry highlighted strong results from BHP’s core assets as the company approaches the wet season in Western Australia. He said it had “delivered another half of very strong performance” and set itself up for a quarter that could disrupt shipments. BHP

The sell-off spread across the board. Tony Sycamore, a market analyst at IG, noted that iron ore futures in Asia dropped 0.87% to $103.75. Rio Tinto shares fell 1.66%, while Fortescue slipped 0.74%, dragging materials stocks lower.

The catch is obvious. Should the China talks stall or product restrictions ramp up, the discount to benchmark prices might widen, throwing flows off balance—even if headline iron ore prices stay steady. Jansen also faces risks from rising labor and materials costs, meaning another cost reset could challenge BHP’s claim that potash will diversify earnings without cutting into returns.

Traders will be closely watching iron ore futures overnight to see if they hold steady, and whether Tuesday’s update is shrugged off as a brief pause or signals a bigger shift in market expectations. The next major event is BHP’s half-year results on Feb. 17, where investors expect more clarity on realised prices, costs, and capital discipline.

Stock Market Today

  • SpaceX Set to Go Public: Key Details and Market Impact
    May 20, 2026, 8:02 PM EDT. SpaceX, founded by Elon Musk, is poised to go public, joining hundreds of companies that raised $70 billion in U.S. equity markets last year. Going public means the company will offer shares for sale on stock exchanges, allowing investors to buy ownership stakes. This move could unlock significant capital for SpaceX's ambitious space ventures, while providing early investors a chance to realize gains. The offering is closely watched amid a strong appetite for tech and aerospace stocks, reflecting broader market interest in innovation-driven firms.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Texas Instruments stock faces a Tuesday gut-check as tariffs rattle tech and earnings loom
Previous Story

Texas Instruments stock faces a Tuesday gut-check as tariffs rattle tech and earnings loom

SEBI listing-rule revamp sparks MSEI unlisted share rally and a hiring rush at NSE, BSE
Next Story

SEBI listing-rule revamp sparks MSEI unlisted share rally and a hiring rush at NSE, BSE

Go toTop